OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Koo on Results From a Survey on Barriers to Prostate Cancer Screening

September 30th 2025

Phillip Koo, MD, discusses findings from a survey of prostate cancer screening rates.

Dr Gellhaus on the Advantages and Limitations of Focal Therapy for Prostate Cancer

September 30th 2025

Paul Gellhaus, MD, discusses ongoing developments with focal therapy in prostate cancer and potential avenues for technological improvement.

Dr Vose on Common Adverse Effects With Epcoritamab in Relapsed/Refractory LBCL

September 30th 2025

Julie M. Vose, MD, MBA, discusses the safety profile of epcoritamab in patients with relapsed/refractory LBCL who have achieved a 2-year complete response.

Dr Lee on Disease-Free Survival Outcomes With Alectinib in ALK+ NSCLC

September 30th 2025

Matthew Lee, MD, details the improved disease-free survival outcomes with adjuvant alectinib in patients with ALK-positive NSCLC.

Dr Mian on Findings From a Dynamic Frailty Analysis in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

September 30th 2025

Hira Mian, MD, discusses findings from a dynamic frailty analysis conducted in transplant-ineligible patients with newly diagnosed multiple myeloma.

Dr Mascarenhas on the Role of Imetelstat in the Myelofibrosis Treatment Paradigm

September 30th 2025

John O. Mascarenhas, MD, discusses the potential role of imetelstat in the treatment of patients with myelofibrosis.

Dr Randall on Challenges Associated With Incorporating Surgical Protocols Into Sarcoma Clinical Trials

September 30th 2025

R. Lor Randall, MD, FACS, discusses the challenges associated with incorporating surgical protocols into clinical trials evaluating sarcoma treatments.

Dr Dietrich on the Limitations of Chemotherapy in Pancreatic Cancer

September 30th 2025

Martin F. Dietrich, MD, PhD, discusses the limitations of frontline chemotherapy in advanced/metastatic pancreatic cancer.

Dr Elez on the Rationale for Evaluating QOL Outcomes With ICI Doublets in mCRC

September 30th 2025

Elena Élez, MD, PhD, discusses quality of life outcomes with combination checkpoint blockade in patients with microsatellite instability-high mCRC.

Dr Shields on the Evolving Role of Prophylactic Cranial Irradiation in SCLC

September 30th 2025

Misty D. Shields, MD, PhD, discusses the modern role for prophylactic cranial irradiation in extensive-stage SCLC management.

Dr Mauro on How Genetic Alterations Impact TKI Decisions in CML

September 30th 2025

Michael J. Mauro, MD, discusses how genetic alterations, such as BCR::ABL mutations, inform treatment decisions in CML.

Dr Kuykendall on the Relevance of QOL End Points in Myelofibrosis Clinical Trials

September 29th 2025

Andrew Kuykendall, MD, discussed the advantages and limitations of using QOL- and symptom-related end points in myelofibrosis clinical research.

Dr Smith on the Use of Doublet vs Triplet Therapies in mHSPC

September 29th 2025

Matthew R. Smith, MD, PhD, discussed patient characteristics and disease factors that influence treatment intensification decisions in mHSPC.

Dr Birhiray on Advancing Clinical Trials in Oncology Using AI Tools and Tactics

September 29th 2025

Ruemu E. Birhiray, MD, discussed the advantages of using AI-based tools to enhance community-based clinical trials in oncology.

Dr Mulherin on Using AI to Address NGS Testing Barriers in Oncology Practice

September 28th 2025

Brian P. Mulherin, MD, discusses using AI tools to improve the implementation of NGS in community oncology practice.

Dr Wilfong on the Potential Use of AI Prediction Models to Improve Palliative Care in Oncology

September 28th 2025

Lalan Wilfong, MD, expands on the value of AI prediction models for consensus on patient prognosis and better end-of-life care in oncology.

Dr Flora on the Potential Role of AI in Clinical Trial Screening and Design for Oncology

September 28th 2025

Douglas Flora, MD, LSSBB, discusses how the use of artificial intelligence tools could improve patient screening and drug development in oncology.

Dr Mascarenhas on the IMpact-MF Trial of Imetelstat in R/R Myelofibrosis

September 26th 2025

John Mascarenhas, MD, outlines the ongoing phase 3 IMpact-MF trial, evaluating imetelstat in relapsed/refractory myelofibrosis.

Dr Vojnic on Vorasidenib in Grade 2 IDH1/2-Mutated Glioma

September 26th 2025

Morana Vojnic, MD, MBA, discusses vorasidenib in grade 2 IDH1/2-mutated glioma.

Dr Sherman on Advances in Surgical Brain Tumor Management

September 26th 2025

Jonathan H. Sherman, MD, FAANS, FCNS, FACS, discusses notable advances in the surgical management of patients with brain tumors.